Skip to main content

AS/Spondyloarthritis

RT @synovialjoints: The C-AxSpand study, Certolizumab-treated nr-axSpA pts with shorter symptom duration (< 5 vs ≥ 5 years) showed greater…

Dr. Antoni Chan synovialjoints

1 year 7 months ago

The C-AxSpand study, Certolizumab-treated nr-axSpA pts with shorter symptom duration (< 5 vs ≥ 5 years) showed greater improvements across signs and symptoms of disease and in quality of life. Kay J et al #ACR19 @RheumNow

×